Welcome to our dedicated page for Loncar China BioPharma ETF news (Ticker: CHNA), a resource for investors and traders seeking the latest updates and insights on Loncar China BioPharma ETF stock.
Loncar China BioPharma ETF (Symbol: CHNA) was an Exchange Traded Fund (ETF) focused on the biotechnology sector within China. It aimed to provide investors with targeted exposure to Chinese pharmaceutical and biotech companies that are contributing significantly to the global healthcare industry.
As of October 20, 2023, the CHNA ETF has been successfully reorganized into the Range Cancer Therapeutics ETF (CNCR). This reorganization was completed by Exchange Traded Concepts, LLC. Upon the Nasdaq Stock Market opening on October 23, 2023, shareholders of CHNA began holding shares of CNCR, with the net asset value (NAV) of these new shares equating to the NAV of their previous CHNA shares.
The reorganization was a taxable event, and shareholders may recognize a gain or loss for federal income tax purposes. Detailed information regarding this process was provided in the Information Statement/Prospectus filed with the SEC. Post-reorganization, CNCR issued approximately 380,835.056 new shares, resulting in total assets of approximately $11,536,010 and a NAV per share of $9.77.
The Loncar China BioPharma ETF, during its operation, was designed to track the performance of a specific index that included key players in China's biopharmaceutical landscape. Investors interested in the sector can continue to access similar opportunities through the CNCR ETF, which now encompasses these holdings.
For up-to-date information and details on the new CNCR ETF, investors are advised to visit the official website at https://www.rangecncr.com/ or contact 1-800-617-0004.
Disclaimer: Investing in ETFs involves risks, including the potential loss of principal. ETFs trade like stocks, and their market prices may vary from their NAV. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing, as detailed in the prospectus.
Defiance ETFs announced its Defiance Next Gen Connectivity ETF (FIVG) has achieved the #1 ranking from Morningstar among 42 funds in the U.S. communications sector over a 3-year period, based on risk-adjusted returns as of 9/30/22. The ETF is recognized for its focus on stocks that contribute to the rollout of 5G communications, contrasting with the Global Industry Classification Standard reclassification. CEO Sylvia Jablonski emphasized FIVG's significance as a core portfolio allocation for investors seeking exposure to the 5G ecosystem.
Fundamental Income has announced an increase in the monthly dividend for its Net Lease Corporate Real Estate ETF (NYSE Arca: NETL) from
FAQ
What is Loncar China BioPharma ETF (CHNA)?
What happened to CHNA shares after the reorganization?
Is the reorganization a taxable event?
What is the NAV of the new CNCR shares?
Where can I find more information about CNCR?
Who is the investment advisor for CNCR?
Are there any risks associated with investing in ETFs like CNCR?
How can I purchase shares of CNCR?
What should investors consider before investing in CNCR?
What is the significance of the reorganization for current CHNA shareholders?
